Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jonathan Chow

Critical Care Medicine Washington, DC Medical Doctor

NPI 1275809261 CMS profile 2133663

2300 M St Nw Fl 7, Washington, DC 20037

Open in the dashboard

General payments

$285,120

196 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$44,446

3 holdings reported · through program year 2025

Through program year 2025, Jonathan Chow of Washington, DC is reported in the CMS Open Payments database as having received $285,120 across 196 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $44,446 across 3 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $21,493 12
2024 General $22,778 8
2023 General $87,685 26
2022 General $55,791 29
2021 General $49,941 40
2020 General $25,357 38
2019 General $22,076 43
2023 Ownership $10,847 1
2022 Ownership $33,599 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jonathan Chow
  • Critical Care Medicine median
  • Middle half of Critical Care Medicine
  • National median

In program year 2025, general payments to Jonathan Chow were reported at $21,493. Among 445 Critical Care Medicine profiles paid that year, the median was $97 and the middle half received between $33 and $255.

Show as a table
Year Jonathan Chow Critical Care Medicine median Middle half National median
2019 $22,076 $103 $29–$256 $163
2020 $25,357 $60 $22–$164 $114
2021 $49,941 $115 $30–$249 $132
2022 $55,791 $97 $27–$196 $149
2023 $87,685 $104 $31–$245 $160
2024 $22,778 $93 $28–$268 $164
2025 $21,493 $97 $33–$255 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. La Jolla Pharmaceutical Company $187,735 162 payments
  2. ExThera Medical Corporation $67,719 15 payments
  3. HemoSonics LLC $29,049 15 payments
  4. Partner Therapeutics, Inc. $350 1 payment
  5. Shionogi Inc $123 1 payment
  6. Chiesi USA, Inc. $103 1 payment
  7. Edwards Lifesciences Corporation $40 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Honoraria $137,808 43 payments
  2. Consulting Fee $78,399 14 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $40,359 11 payments
  4. Travel and Lodging $24,279 66 payments
  5. Food and Beverage $4,275 62 payments
Products named General payments · program years 2019–2025
  1. GIAPREZA Emergent Hypotension $163,056 120 payments
  2. QUNATRA QPLUS SYSTEM $28,143 11 payments
  3. GIAPREZA Giapreza $21,865 41 payments
  4. QUANTRA QPLUS SYSTEM $16,316 10 payments
  5. XERAVA $2,815 1 payment
  6. QUANTRA QPLUS SYSTEM Hematology $798 3 payments
  7. Leukine $350 1 payment
  8. Fetroja $123 1 payment
  9. Quantra QPlus System Hematology $108 1 payment
  10. CLEVIPREX $103 1 payment
  11. Other $40 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$18,425

Medicare's payments for the services billed

Medicare patients

81

Average age 69

Services billed

116

37 women, 44 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 56%
Diabetes 53%
Arthritis 53%
Chronic kidney disease 49%
Heart failure 44%
COPD 38%
Depression 36%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

196 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Critical Care Medicine in District of Columbia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record